Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Leading Players Driving Innovation in the Circadian Rhythm Sleep Treatment Market Key players in that circadian rhythm sleep treatment market are Vanda Pharmaceuticals, Inc., Akeda Pharmaceutical ...

Leading Players Driving Innovation in the Circadian Rhythm Sleep Treatment Market Key players in that circadian rhythm sleep treatment market are Vanda Pharmaceuticals, Inc., Akeda Pharmaceutical ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food ...

With California wildfires triggering a massive rebuilding process that could take several years, investors are looking closer at lumber stocks.

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Years of scouring the bush and breeding work at The University of Queensland have resulted in new varieties of a native Australian plant valuable to the global pharmaceutical industry. Researchers ...

Begin your TipRanks Premium journey today. Vanda (VNDA) Company Description: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs.

Tradipitant is under clinical development by Vanda Pharmaceuticals and currently in Phase III for Motion Sickness. According to GlobalData, Phase III drugs for Motion Sickness have a 100% phase ...

VHX-896 is under clinical development by Vanda Pharmaceuticals and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 68% phase transition ...